Press release
Lawsuit filed for Investors who lost mone with shares of BioLineRx Ltd. (NASDAQ: BLRX)
A lawsuit was filed on behalf of investors in BioLineRx Ltd. (NASDAQ: BLRX) shares over alleged securities laws violations.
Investors who purchased shares of BioLineRx Ltd. (NASDAQ: BLRX) have certain options and for certain investors are short and strict deadlines running. Deadline: March 6, 2023. NASDAQ: BLRX investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
Israel based BioLineRx Ltd., a clinical-stage biopharmaceutical development company, focuses on oncology. BioLineRx Ltd.
BioLineRx Ltd. reported that its Net Loss declined from $30.02 million in 2020 to $27.05 million in 2021.
On September 19, 2022, BioLineRx filed a Form 6-K attaching its press release, which stated, it had "entered into definitive agreements with several institutional investors for the issuance and sale in a registered direct offering of 13,636,365 of the Company's American Depositary Shares (ADSs) and warranted to purchase up to an aggregate of 13,636,365 ADSs, at a combined purchase price of $1.10 per ADS and associated warrant. Each ADS represents fifteen (15) ordinary shares, par value NIS 0.10 per share, of BioLineRx." The press release continued, stating, "[t]he gross proceeds from the offering … are expected to be $15 million. BioLineRx intends to use the net proceeds to facilitate the commercial launch of Motixafortide in autologous stem cell mobilization for multiple myeloma patients and general corporate purposes, which may include working capital and funding clinical trials…"
Shares of BioLineRx Ltd. (NASDAQ: BLRX) declined from $3.15 per share on October 15, 2021, to as low as $0.84 per share on September 26, 2022.
The plaintiff claims that between February 23, 2021 and September 19, 2022, the defendants made false and/or misleading statements and/or failed to disclose, among other things, that the Company was not well financed to develop Motixafortide while at the same time advancing other pipeline programs, that BioLine would require a loan from Kreos Capital VII Aggregator SCSP in an aggregate principal amount of up to $40 million and then also would require a $15M securities offering to facilitate the commercial launch of Motixafortide, and that as a result of the foregoing, defendants' statements about its business, operations, and prospects, were materially false and misleading and/or lacked a reasonable basis at all relevant times.
Those who purchased shares of BioLineRx Ltd. (NASDAQ: BLRX) have certain options and should contact the Shareholders Foundation.
Contact:
Michael Daniels
Shareholders Foundation, Inc.
3111 Camino Del Rio North
Suite 423
San Diego, CA 92108
Tel: +1-(858)-779-1554
E-Mail: mail@shareholdersfoundation.com
About Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, and an investor advocacy group, which does research related to shareholder issues and informs investors of securities lawsuits, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigations, and/or settlements are not filed/initiated/reached and/or are not related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Lawsuit filed for Investors who lost mone with shares of BioLineRx Ltd. (NASDAQ: BLRX) here
News-ID: 2879862 • Views: …
More Releases from Shareholders Foundation
Lawsuit for Investors in Sonder Holdings Inc. (NASDAQ: SOND) filed in effort to …
An investor, who purchased shares of Sonder Holdings Inc. (NASDAQ: SOND), filed a lawsuit over alleged violations of Federal Securities Laws by Sonder Holdings Inc in connection with certain allegedly false and misleading statements.
Investors who purchased shares of Sonder Holdings Inc. (NASDAQ: SOND) have certain options and for certain investors are short and strict deadlines running. Deadline: June 10, 2024. NASDAQ: SOND investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com…
Lawsuit filed for Investors in Ocugen, Inc. (NASDAQ: OCGN) in effort to recover …
An investor, who purchased shares of Ocugen, Inc. (NASDAQ: OCGN), filed a lawsuit i over alleged violations of Federal Securities Laws by Ocugen, Inc..
Investors who purchased shares of Ocugen, Inc. (NASDAQ: OCGN) have certain options and for certain investors are short and strict deadlines running. Deadline: June 10, 2024. NASDAQ: OCGN investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
Malvern, PA based Ocugen, Inc., a…
Investors who lost money with shares of Evolv Technologies Holdings, Inc. (NASDA …
An investor, who purchased shares of Evolv Technologies Holdings, Inc. (NASDAQ: EVLV), filed a lawsuit in the U.S. District Court for the District of Massachusetts over alleged violations of Federal Securities Laws by Evolv Technologies Holdings, Inc. f/k/a NewHold Investment Corp.
Investors who purchased shares of Evolv Technologies Holdings, Inc. (NASDAQ: EVLV) have certain options and for certain investors are short and strict deadlines running. Deadline: May 24, 2024. NASDAQ: EVLV…
Investigation announced for Investors who purchased shares of Comtech Telecommun …
Comtech Telecommunications Corp is under investigation over potential securities laws violations in connection with certain financial statements.
Investors who purchased shares of Comtech Telecommunications Corp. (NASDAQ: CMTL), have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm focuses on whether a series of statements by Comtech Telecommunications Corp. regarding its business, its prospects and its operations were materially false…
More Releases for BioLine
Biostimulants Market Growth Opportunities Investment Analysis Report 2022-2032 | …
Global Biostimulants Market research report 2022-2032 is a genuine overview and in-depth study on the current and future industry of the Biostimulants industry. The Biostimulants Market report provides supreme data, such as development strategy, competitive landscape, environment, opportunities, risk, challenges, and barriers, value chain optimization, contact and income information, technological advancement, product offerings of key players, and the dynamic structure of the domain. The Biostimulants industry report provides growth rate, recent trends, and…
Beneficial Insects Market Overview and Outlook Report by 2026| Biobest, Bioline …
Los Angeles, United State, June 10th, 2020, - The global Beneficial Insects market is carefully researched in the report while largely concentrating on top players and their business tactics, geographical expansion, market segments, competitive landscape, manufacturing, and pricing and cost structures. Each section of the research study is specially prepared to explore key aspects of the global Beneficial Insects market. For instance, the market dynamics section digs deep into the…
Chitosan Gel Market By Size, Share, Development 2026| ADVANCED BIOPOLYMERS, Nova …
Latest Report On Chitosan Gel Market including Market Landscape, and Market size, Revenues by players, Revenues by regions, Average prices, Competitive landscape, market Dynamics and industry trends and developments during the forecast period.
The global Chitosan Gel market is broadly analyzed in this report that sheds light on critical aspects such as the vendor landscape, competitive strategies, market dynamics, and regional analysis. The report helps readers to clearly understand the…
Global Hydrothermal Autoclave Market 2018 -TechInstro, Tefic Biotech, Bioline Te …
Apex Market Reports, recently published a detailed market research study focused on the “Hydrothermal Autoclave Market” across the global, regional and country level. The report provides 360° analysis of “Hydrothermal Autoclave Market” from view of manufacturers, regions, product types and end industries. The research report analyses and provides the historical data along with current performance of the global PP Pipe industry, and estimates the future trend of Hydrothermal Autoclave on…
Global Competent Cells Market Research Report 2017 : Lucigen, Bioline, Genewiz
Qyresearchreports include new market research report "Global Competent Cells Market Research Report 2017" to its huge collection of research reports.
This report on the global Competent Cells market is highly detailed, covering all the important aspects of the market. With overwhelming amount of information available on the web about the global Competent Cells market, it becomes impossible to decide what is important and what is not. Expert researchers with much market…
Hydrothermal Autoclave Market 2017- TechInstro, Bioline Technologies, Precious T …
Apex Market Reports, recently published a detailed market research study focused on the "Hydrothermal Autoclave Market" across the global, regional and country level. The report provides 360° analysis of "Hydrothermal Autoclave Market" from view of manufacturers, regions, product types and end industries. The research report analyses and provides the historical data along with current performance of the global Hydrothermal Autoclave industry, and estimates the future trend of Hydrothermal Autoclave market…
